Actuate Therapeutics Highlights Biomarker, Machine Learning Data From Phase 2 Elraglusib Trial In First-Line Treatment Of Metastatic Pancreatic Cancer

Author: Benzinga Newsdesk | June 20, 2025 07:48am

The poster described an analysis of 40 cytokines, chemokines, soluble cell receptors, and growth factors (CCSGs) from plasma samples obtained prior to treatment from all patients enrolled in Actuate-1801 Part 3B. The analysis identified 7 biomarkers as uniquely significant predictors of favorable survival in the elraglusib-treated cohort, including one, CXCL2, with an inverse survival trend compared to the GnP control arm. This indicates that in patients not treated with elraglusib, high CXCL2 was unfavorable, but this trend is reversed with elraglusib treatment, highlighting the potential of elraglusib to favorably affect the immune microenvironment.

Posted In: ACTU